Interaction of the single-particle and collective degrees of freedom in non-magic nuclei: the role of phonon tadpole terms

A method of a consistent consideration of the phonon contributions to mass and gap operators in non-magic nuclei is developed in the so-called g^2 approximation, where g is the low-lying phonon creation amplitude. It includes simultaneous accounting for both the usual non-local terms and the phonon tadpole ones. The relations which allow the tadpoles to be calculated without any new parameters are derived. As an application of the results, the role of the phonon tadpoles in the single-particle strength distribution and in the single-particle energies and gap values has been considered. Relation to the problem of the surface nature of pairing is discussed.Comment: 22 pages, 7 figure

Induced Parity Nonconserving Interaction and Enhancement of Two-Nucleon Parity Nonconserving Forces

Two-nucleon parity nonconserving (PNC) interaction induced by the single-particle PNC weak potential and the two-nucleon residual strong interaction is considered. An approximate analytical formula for this Induced PNC Interaction (IPNCI) between proton and neutron is derived ($Q({\bf r} {\bf \sigma}_{p} \times {\bf \sigma}_{n}) \delta({\bf r}_{p}-{\bf r}_{n})$), and the interaction constant is estimated. As a result of coherent contributions from the nucleons to the PNC potential, IPNCI is an order of magnitude stronger ($\sim A^{1/3}$) than the residual weak two-nucleon interaction and has a different coordinate and isotopic structure (e.g., the strongest part of IPNCI does not contribute to the PNC mean field). IPNCI plays an important role in the formation of PNC effects, e.g., in neutron-nucleus reactions. In that case, it is a technical way to take into account the contribution of the distant (small) components of a compound state which dominates the result. The absence of such enhancement ($\sim A^{1/3}$) in the case of T- and P-odd interaction completes the picture.Comment: Phys. Rev. C, to appear; 17 pages, revtex 3, no figure

NESTOR: A neutrino particle astrophysics underwater laboratory for the Mediterranean

Abstract An underwater neutrino astrophysics laboratory, to be located in the international waters off the Southwest of Greece, near the town of Pylos is now under construction. In the last two years a group of physicists from Greece and Russia have carried out two demonstration experiments in 4km deep water, counting muons and verifying the adequacy of the deep sea site. Plans are presented for a 100, 000 m 2 high energy neutrino detector composed of a hexagon of hexagonal towers, with 1176 optical detector units. A progress report is given and the physics potential of a siggle tower with 168 phototubes (currently under construction) is described

Neutrino Cooling of Neutron Stars. Medium effects

This review demonstrates that neutrino emission from dense hadronic component in neutron stars is subject of strong modifications due to collective effects in the nuclear matter. With the most important in-medium processes incorporated in the cooling code an overall agreement with available soft X ray data can be easily achieved. With these findings so called "standard" and "non-standard" cooling scenarios are replaced by one general "nuclear medium cooling scenario" which relates slow and rapid neutron star coolings to the star masses (interior densities). In-medium effects take important part also at early hot stage of neutron star evolution decreasing the neutrino opacity for less massive and increasing for more massive neutron stars. A formalism for calculation of neutrino radiation from nuclear matter is presented that treats on equal footing one-nucleon and multiple-nucleon processes as well as reactions with resonance bosons and condensates. Cooling history of neutron stars with quark cores is also discussed.Comment: To be published in "Physics of Neutron Star Interiors", Eds. D. Blaschke, N.K. Glendenning, A. Sedrakian, Springer, Heidelberg (2001

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362